Hipra demonstrates the benefits of its Yurvac RHD vaccine at the 13th WRC

Taking advantage one of the most important conferences for rabbit farming, for example, World Rabbit CongressHipra presented 6 studies on the effectiveness against the most virulent strains of RHDV2 and the benefits obtained after using Yurvac.^® Right-hand drive.

Sandra Gascón Torrance (Hipra Global Product Manager) and Massimiliano Baratelli (Business Partner R&D Post Marketing Studies) were responsible for presenting the work and answering questions from participants who showed great interest in the results obtained.

A large-scale field study was carried out during which included almost 6,000 rabbitswhich made it possible to evaluate the safety of the vaccine and the serological response in animals vaccinated in the presence of maternal immunity.

Among the main findings of these studies, they concluded that Jurvak^® right-hand drive it’s effective against the highly virulent strain RHDV2, as well as against the classical strain. Other results from these studies include effectiveness in stop outbreaks of rabbit hemorrhagic disease

and in protecting rabbits from various strains of rabbit hemorrhagic disease.

Likewise, it can be used in pregnant and lactating rabbits without affecting reproductive parameters, and its protection has been demonstrated in young rabbits from vaccinated rabbits, providing maternal immunity, at least for now 30 days to live.

In addition to Jurvak’s research^® RHD, also presented a seventh poster on myxomatosis, demonstrating that revaccination of rabbits with MIXOHIPRA-H has no negative impact about your immunity.

“Through research and participation in this event, Hipra demonstrates its commitment to the rabbit sector“, they emphasize from the laboratory.